2025 ICD-10-CM Diagnosis Code E79

by

Disorders of purine and pyrimidine metabolism

  • E79 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2025 edition of ICD-10-CM E79 became effective on October 1, 2024.
  • This is the American ICD-10-CM version of E79 – other international versions of ICD-10 E79 may differ.

Type 1 Excludes

  • Ataxia-telangiectasia (Q87.19)
  • Bloom’s syndrome (Q82.8)
  • Cockayne’s syndrome (Q87.19)
  • calculus of kidney (N20.0)
  • combined immunodeficiency disorders (D81.-)
  • Fanconi’s anemia (D61.09)
  • gout (M1A.-, M10.-)
  • orotaciduric anemia (D53.0)
  • progeria (E34.8)
  • Werner’s syndrome (E34.8)
  • xeroderma pigmentosum (Q82.1)

The following code(s) above E79 contain annotation back-references

 that may be applicable to E79:

  • E00-E89  Endocrine, nutritional and metabolic diseases
  • E70-E88  Metabolic disorders

Clinical Information

  • Condition in which there is a deviation or interruption in the processing of purine or pyrmidine in the body: its absorption, transport, storage, and utilization.

Code History

  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
  • 2024 (effective 10/1/2023): No change
  • 2025 (effective 10/1/2024): No change

Code annotations containing back-references to E79:

  • Type 1 Excludes: E72
  • Type 2 Excludes: G11.3
error: Content is protected !!